Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for progressive fibrosing interstitial lung disease (non-IPF)
ChiCTR2100042720Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of pirfenidone in interstitial lung disease (ILD) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Lung function. Started Feb 2021; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2100042720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042720.